Senior Housing News July 24, 2024
Swiss-based biotech company Asceneuron has successfully raised an additional $100 million for the development of drug therapies that target proteins linked to Alzheimer’s disease and other cognitive brain conditions.
The Series C financing will advance the clinical development of drug therapies known as OGA inhibitors for the treatment of neurodegenerative diseases, according to the company. The fundraise was led by Novo Holdings.
The $100 million fundraise will advance Asceneuron’s ASN51 drug therapy into a new phase for clinical development for the treatment of Alzheimer’s disease. The drug is designed to inhibit OGA, an enzyme involved in protein aggregation seen in Alzheimer’s patients.
“We are excited to advance our lead asset ASN51 into Phase 2 clinical development, recognizing its potential to...
Today's Sponsors
Today's Sponsor